Sheryl L Gstalder-chaney, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 126 Trivette Drive, Suite 101, Pikeville, KY 41501 Phone: 606-432-0003 Fax: 606-432-0076 |
Pikeville Medical Center Inc. Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 911 Bypass Rd, Pikeville, KY 41501 Phone: 606-218-3500 Fax: 606-218-4562 |
Bradwell Scott Chaney, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 126 Trivette Drive, Suite 101, Pikeville, KY 41501 Phone: 606-432-0003 Fax: 606-432-0076 |
Dr. Mariano Emi Rivera, D.P.M Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 911 Bypass Rd Bldg A, Pikeville, KY 41501 Phone: 606-430-2206 Fax: 606-218-7506 |
Magdy Issa, DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 911 Bypass Rd Bldg A, Pikeville, KY 41501 Phone: 606-430-2206 Fax: 606-218-7506 |
Matthew Quinn Mccammon, DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 911 Bypass Rd Bldg A, Pikeville, KY 41501 Phone: 606-430-7506 Fax: 606-218-7506 |
News Archive
The U.S. Food and Drug Administration today approved Lymphoseek (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumor-draining lymph nodes.
In 1998, MMR vaccinations in the United Kingdom reached 92% of its targets. Yet by 2002, after claims of a possible relation between MMR and autism, the United Kingdom lost considerable ground. One of the lowest levels of coverage of MMR is now found in London, at around 75%.
Remotely monitored in-home virtual reality videogames improved hand function and forearm bone health in teens with hemiplegic cerebral palsy, helping them perform activities of daily living such as eating, dressing, cooking, and other tasks for which two hands are needed.
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.
As the novel coronavirus spread across the globe in early 2020, hospitals worldwide scaled back medical procedures, including life-saving heart surgery, to deal with the emerging threat of COVID-19.
› Verified 8 days ago